Zhang Xiao, Wang Yadong, Yu Miao, Huang Jinzhao, Deng Dongfeng, Xue Huanzhou
Department of Hepatic Biliary Pancreatic Surgery, People's Hospital of Zhengzhou University , Zhengzhou, China .
J Laparoendosc Adv Surg Tech A. 2017 Mar;27(3):247-252. doi: 10.1089/lap.2016.0511. Epub 2017 Feb 16.
Portal venous system thrombosis (PVST) is a common and potentially life-threatening complication of splenectomy for portal hypertension due to cirrhosis.
A meta-analysis was conducted to study the necessity of pharmacologic prophylaxis of PVST after splenectomy and how to select the feasible treatment method. Articles were searched through the PubMed, EMBASE, Cochrane Library databases, and CNKI.
Overall, 404 articles were initially identified, and 11 of them were eligible. Among these selected articles, 7 articles were associated with the necessity of anticoagulation for prevention of PVST, while 5 were about the drug selection. We first demonstrated that the incidence of PVST after splenectomy was significantly lower in patients who received the preventive measures than in those who did not (odds ratio [OR]: 0.22, 95% confidence interval [CI]: 0.13-0.39, P < .00001). Then, we compared the new-style treatment with the conventional treatment and found that patients with new therapy method had lower incidence of PVST than those who received conventional treatment (OR: 0.37, 95% CI: 0.27-0.51, P < .00001). Also, some studies (n = 4) reported that early and combination use of anticoagulation drugs can lead to better outcome for patients with splenectomy and devascularization.
Preventative use of anticoagulant drugs might decrease the incidence of PVST after splenectomy in patients with portal hypertension, new anticoagulant drugs such as low-molecular-weight heparin should be used, and early or combination use of anticoagulation drugs might lead to lower PVST incidence for patients.
门静脉系统血栓形成(PVST)是肝硬化所致门静脉高压脾切除术后常见且可能危及生命的并发症。
进行一项荟萃分析,以研究脾切除术后药物预防PVST的必要性以及如何选择可行的治疗方法。通过PubMed、EMBASE、Cochrane图书馆数据库和中国知网检索文章。
总体而言,最初鉴定出404篇文章,其中11篇符合条件。在这些选定的文章中,7篇与抗凝预防PVST的必要性相关,而5篇与药物选择有关。我们首先证明,接受预防措施的患者脾切除术后PVST的发生率明显低于未接受预防措施的患者(优势比[OR]:0.22,95%置信区间[CI]:0.13 - 0.39,P <.00001)。然后,我们将新型治疗与传统治疗进行比较,发现采用新治疗方法的患者PVST发生率低于接受传统治疗的患者(OR:0.37,95%CI:0.27 - 0.51,P <.00001)。此外,一些研究(n = 4)报告称,早期联合使用抗凝药物可使脾切除和去血管化患者获得更好的结局。
预防性使用抗凝药物可能会降低门静脉高压患者脾切除术后PVST的发生率,应使用低分子量肝素等新型抗凝药物,早期或联合使用抗凝药物可能会降低患者的PVST发生率。